Status:

COMPLETED

Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study

Lead Sponsor:

Cyberonics, Inc.

Conditions:

Congestive Heart Failure

Eligibility:

All Genders

18+ years

Phase:

PHASE1

PHASE2

Brief Summary

The ANTHEM-HF Study is designed to demonstrate the safety and efficacy of vagus nerve stimulation (VNS) with the Cyberonics VNS Therapy System for the treatment of subjects with symptomatic heart fail...

Detailed Description

Heart failure patients will be enrolled and randomized to cervical VNS implantation on either the left side or right side. After a 2-week post-implantation recovery period and a 10-week stimulation ti...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Patients with symptomatic heart failure, New York Heart Association (NYHA) class II/III with reduced EF and dilated hearts

Exclusion

    Key Trial Info

    Start Date :

    July 1 2012

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    June 1 2014

    Estimated Enrollment :

    60 Patients enrolled

    Trial Details

    Trial ID

    NCT01823887

    Start Date

    July 1 2012

    End Date

    June 1 2014

    Last Update

    February 19 2015

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Chennai, India

    Autonomic Neural Regulation Therapy to Enhance Myocardial Function in Heart Failure (ANTHEM-HF) Study | DecenTrialz